Silencing Bcl-XL in cancer therapy by 源�嫄댄솉
©2
005
 LA
ND
ES 
BIO
SCI
EN
CE.
 DO
 NO
T D
IST
RIB
UT
E.
[Cancer Biology & Therapy 4:4, 398-399, April 2005]; ©2005 Landes Bioscience
398 Cancer Biology & Therapy 2005; Vol. 4 Issue 4
Kunhong Kim
Correspondence to: Kunhong Kim; Department of Biochemistry and Molecular
Biology; BK21 Project for Medical Sciences; Yonsei University College of Medicine;
Nanomedical National Core Research Center; 134 Shinchon-Dong; Seodaemoon-gu,
Seoul 120-752 Korea; Email: kimkh34@yumc.yonsei.ac.kr
Received 04/23/05; Accepted 04/27/05
Previously published online as a Cancer Biology & Therapy E-publication:
http://www.landesbioscience.com/journals/cbt/abstract.php?id=1761
KEY WORDS
TRAIL, Bcl-XL, siRNA, apoptosis
Commentary to:
Enhancing TRAIL-Induced Apoptosis by Bcl-XL siRNA
Hongbo Zhu, Wei Guo, Lidong Zhang, John J. Davis,
Shuhong Wu, Fuminori Teraishi, Xiaobo Cao, W. Roy
Smythe and Bingliang Fang
Commentary
Silencing Bcl-XL in Cancer Therapy
There are two main signaling pathways that lead to apoptosis: an “extrinsic” and an
“intrinsic” pathway. The Tumor Necrosis Factor (TNF)-related apoptosis-inducing ligand
(TRAIL) triggers the extrinsic pathway and is a promising agent for development as a
cancer therapeutic1 because it appears to specifically kill transformed and cancer cells,
whereas most normal cells appear to be resistant to TRAIL.2,3 TRAIL binding to either of
two pro-apoptotic TRAIL death receptors, TRAIL R1 (DR4)4 or TRAIL R2 (KILLER/
DR5),5 induces the formation of a death-inducing signaling complex (DISC), which
consists of one of the TRAIL receptors, the adaptor protein FADD,6 and an initiator caspase,
procaspase-8. Once the DISC is formed, procaspase-8 is auto-processed and activated by
induced proximity.7 The activated caspase-8 can directly activate the executioner caspase,
caspase-3, without the involvement of the mitochondrial pathway (type I pathway), or it
can cleave Bid. Truncated cleaved Bid (tBid) exposes a new amino-terminal glycine that
undergoes post-translational myristoylation.8 The myristoylated Bid translocates to the
mitochondria where tBid inserts into the membrane9 followed by Bax translocation, Bak
oligomerization, and cytochrome c release (type II pathway).10
The intrinsic pathway in response to DNA damage, such as that caused by radio- and
chemotherapeutic agents11,12 involves the participation of mitochondria, which release
cytochrome c.8 The released cytosolic cytochrome c induces oligomerization of Apaf-1 and
recruitment of procaspase-9 into a large complex known as the apoptosome.13 After
activation in the apoptosome, caspase-9 activates the effector caspases,13,14 thereby initi-
ating apoptosis.
The Bcl-2 family proteins are the major regulators of mitochondrial apoptotic home-
ostasis.15 Several members of the Bcl-2 family (including Bcl-2, Bcl- XL, MCL-1, A1 and
BAG-1) promote survival while the other members (including Bcl-XS, Bad, Bax, and Bak)
promote cell death. The relative ratios of these pro- and anti-apoptotic members (i.e.,
homodimers:heterodimers) of the Bcl-2 family, rather than the expression level of any
single Bcl-2 family protein, have been shown to determine the ultimate apoptotic sensitivity
or resistance of cells to diverse stimuli.16 Anti-apoptotic proteins including Bcl-2 or Bcl-XL
are frequently overexpressed in human tumors,17 thereby blocking death signal propagation
through mitochondria.18 Accordingly, targeted knock-down or silencing of the anti-apop-
totic Bcl-2 family has potential to facilitate cancer cell apoptosis induced by various
apoptotic stimuli. Until recently, the repression of these genes has been mediated by
anti-sense oligonucleotides. The oligonucleotides targeting Bcl-XL could sensitize tumor
cells to various chemotherapeutic agents,19 agonistic anti-FAS Ab,20 or to TRAIL.21,22
Recently small interfering RNAs (siRNAs) that are 21- to 23 nucleotides of dsRNA23 have
emerged for repression of these genes. For example, Bcl-XL protein expression was silenced
by Bcl-XL-specific synthetic siRNA in 5-FU-resistant cancer cells and proliferation of the
cells became inhibited by 5-FU.24
In the present study, Zhu et al show that the combination of Bcl-XL siRNA and TRAIL
inhibited cell proliferation and sensitized TRAIL-induced apoptosis in human cancer cells
with both acquired (DLD1-TRAIL/R, a TRAIL-resistant derivative selected from human
colon cancer DLD-1 parental cells) and intrinsic (human ovarian cancer SKOV3 cells,
which express high levels of Bcl-XL and have K441R polymorphism in the death domain
of DR425) TRAIL resistance. The results show that although there is detectable
cytochrome-c release into cytosol by Bcl-XL siRNA alone, TRAIL alone, or the combination
of Bcl- XL siRNA and TRAIL in both cell lines, there was no release of Smac/DIA-
BLO26,27 from mitochondria in any of the treatment groups. Smac/DIABLO is normally
localized to mitochondria but is released into the cytosol during the early stages of apoptosis,
where it promotes caspase activity by inhibiting IAPs, particularly the X-linked inhibitor
of apoptosis (XIAP).28,29 Overexpression of Bcl-XL prevented mitochondrial release of
Smac/DIABLO and subsequent inactivation of the XIAP protein.30 Overexpression of
the IAP family proteins is associated with poor responsiveness to apoptosis-inducing
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therapies.31,32 Therefore, it is possible that the outcome of treatment
using the combination of Bcl-XL siRNA and TRAIL may be affected
by the expression level of endogenous XIAP in cancer cells.
To have broad applications for cancer therapy, the downregulation
of Bcl-XL should have minimal cytotoxicity toward normal cells.
Although severe clinical side effects related to the transient down-
regulation of Bcl-XL or Bcl-2 in normal cells and other normal tissues
have not been reported, there was a report that normal cells under-
went apoptosis upon treatment with Bcl-XL or Bcl-2/Bcl-XL
anti-sense oligonucleotides.33 To avoid this potential side effect,
Bcl-XL siRNA should either be delivered to the target cells in a
tumor-specific manner or the target Bcl-XL should be specifically
expressed in the tumors being treated. Recently, there have been
reports on schemes that could be used to express siRNAs in a tissue
specific manner.34,35 By modifying these schemes, Bcl-XL siRNA
could be expressed specifically in cancer cells and thus, unwanted
cytotoxicity toward normal cells could be circumvented and thera-
peutic sensitization of cancer cells toward TRAIL or other cancer
chemotherapeutics could be achieved.
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